Research outputs
2025
Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia
Lim, Y. J., Duckworth, A. D., Clarke, K., Kennedy, P., Karpha, I., Oates, M., . . . Pettitt, A. R. (2025). Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia. Frontiers in Immunology, 16. doi:10.3389/fimmu.2025.1528405
2023
Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL)
Lim, Y. J., Duckworth, A., Clarke, K., Kennedy, P., Oates, M., Gornall, M., . . . Pettitt, A. (2023). Deep Immune Profiling Identifies Novel T-Cell Subpopulations That Influence Specific Clinical Outcomes in Chronic Lymphocytic Leukaemia (CLL). Blood, 142(Supplement 1), 4626. doi:10.1182/blood-2023-185091
High Dimensional Detection of Non-Malignant B-Cells and Its Clinical Implications in Patients with Chronic Lymphocytic Leukaemia (CLL) Undergoing Frontline Therapy
Lim, Y. J., Duckworth, A., Clarke, K., Oates, M., Gornall, M., Kalakonda, N., . . . Pettitt, A. (2023). High Dimensional Detection of Non-Malignant B-Cells and Its Clinical Implications in Patients with Chronic Lymphocytic Leukaemia (CLL) Undergoing Frontline Therapy. Blood, 142(Supplement 1), 1894. doi:10.1182/blood-2023-185018
Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL)
Lim, Y. J., Duckworth, A., Clarke, K., Oates, M., Gornall, M., Kalakonda, N., . . . Pettitt, A. (2023). Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL). Blood, 142(Supplement 1), 1455. doi:10.1182/blood-2023-185063
Independent Predictors of Repeat Emergency Room Presentations: Insights from a Cohort of 1066 Consecutive Patients with Non-Cardiac Chest Pain Generating 4770 Repeat Presentations
Khand, A., Brankin-Frisby, T., Gornall, M., Hatherley, J., Raj, R., Campbell, M., . . . Grainger, R. (2023). Independent Predictors of Repeat Emergency Room Presentations: Insights from a Cohort of 1066 Consecutive Patients with Non-Cardiac Chest Pain Generating 4770 Repeat Presentations. JOURNAL OF CLINICAL MEDICINE, 12(16). doi:10.3390/jcm12165290
Short-Term functional comparison of three total knee arthroplasties-Journey II, Genesis II and Profix.
Guta, D., Santini, A. J., Gornall, M., Phillipson, A., Davidson, J. S., Banks, J., . . . Yorke, J. (2023). Short-Term functional comparison of three total knee arthroplasties-Journey II, Genesis II and Profix.. Journal of orthopaedic surgery (Hong Kong), 31(1), 10225536231169572. doi:10.1177/10225536231169572
2022
Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 Studies
Braconi, D., Geminiani, M., Psarelli, E. E., Giustarini, D., Marzocchi, B., Rossi, R., . . . Santucci, A. (2022). Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 Studies. CELLS, 11(22). doi:10.3390/cells11223668
Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone
Imrich, R., Sedlakova, J., Ulehlova, M., Gornall, M., Jackson, R., Olsson, B., . . . Ranganath, L. R. (2022). Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone. RMD OPEN, 8(2). doi:10.1136/rmdopen-2022-002422
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
Hussain, S. A., Lester, J. F., Jackson, R., Gornall, M., Qureshi, M., Elliott, A., . . . Jones, R. J. (2022). Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. LANCET ONCOLOGY, 23(5), 650-658. doi:10.1016/S1470-2045(22)00158-9
Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria
Ranganath, L. R., Milan, A. M., Hughes, A. T., Davison, A. S., Khedr, M., Norman, B. P., . . . Olsson, B. (2022). Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria. Molecular Genetics and Metabolism Reports, 30, 100846. doi:10.1016/j.ymgmr.2022.100846
Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.
Ranganath, L. R., Milan, A. M., Hughes, A. T., Khedr, M., Norman, B. P., Alsbou, M., . . . Jackson, R. (2022). Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.. JIMD reports, 63(1), 80-92. doi:10.1002/jmd2.12261
2020
Independent predictors of repeat emergency room presentations in patients with noncardiac chest pain: insights from a cohort of 1066 consecutive patients with 4770 repeat presentations
Yang, Y. H., Grainger, R., Gornall, M., Obeidat, M., Campbell, M., Batouskaya, K., & Khand, A. (2020). Independent predictors of repeat emergency room presentations in patients with noncardiac chest pain: insights from a cohort of 1066 consecutive patients with 4770 repeat presentations. In EUROPEAN HEART JOURNAL Vol. 41 (pp. 3529). Retrieved from https://www.webofscience.com/
NO DIFFERENCE BETWEEN A BICRUCIATE STABILISING KNEE AND CRUCIATE RETAINING KNEE REGARDS TO FUNCTIONAL OUTCOMES OVER THE BMI RANGE
Seth, S., Gornall, M., Davidson, J., Banks, J., Phillipson, A., Pope, J., & Santini, A. (2020). NO DIFFERENCE BETWEEN A BICRUCIATE STABILISING KNEE AND CRUCIATE RETAINING KNEE REGARDS TO FUNCTIONAL OUTCOMES OVER THE BMI RANGE. The Knee, 27, S26. doi:10.1016/j.knee.2020.07.063
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.
Whittam, D. H., Cobo-Calvo, A., Lopez-Chiriboga, A. S., Pardo, S., Gornall, M., Cicconi, S., . . . Jacob, A. (2020). Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.. Multiple sclerosis and related disorders, 44. doi:10.1016/j.msard.2020.102251
Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE).
Hussain, S. A., Lester, J. F., Jackson, R., Gornall, M., Elliott, A., Crabb, S. J., . . . Jones, R. J. (2020). Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE).. Journal of Clinical Oncology, 38(6_suppl), 438. doi:10.1200/jco.2020.38.6_suppl.438